BACTROBAN Drug Patent Profile

Which patents cover Bactroban, and what generic alternatives are available?

Bactroban is a drug marketed by Glaxosmithkline and is included in three NDAs.

The generic ingredient in BACTROBAN is mupirocin. There are sixteen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the mupirocin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Bactroban

A generic version of BACTROBAN was approved as mupirocin by PADAGIS ISRAEL on November 7^th, 2003.

Summary for BACTROBAN

US Patents:	0
Applicants:	1
NDAs:	3
Raw Ingredient (Bulk) Api Vendors:	87
Clinical Trials:	19
Patent Applications:	5,056
Drug Prices:	Drug price information for BACTROBAN
What excipients (inactive ingredients) are in BACTROBAN?	BACTROBAN excipients list
DailyMed Link:	BACTROBAN at DailyMed

See drug prices for BACTROBAN

See drug sales revenues for BACTROBAN

Recent Clinical Trials for BACTROBAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Lindenhofgruppe AG	Phase 4
Lindenhof AG	Phase 4
Indiana University	Phase 2

See all BACTROBAN clinical trials

US Patents and Regulatory Information for BACTROBAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	BACTROBAN	mupirocin calcium	CREAM;TOPICAL	050746-001	Dec 11, 1997		DISCN	Yes	No
Glaxosmithkline	BACTROBAN	mupirocin calcium	OINTMENT;NASAL	050703-001	Sep 18, 1995		DISCN	Yes	No
Glaxosmithkline	BACTROBAN	mupirocin	OINTMENT;TOPICAL	050591-001	Dec 31, 1987		DISCN	Yes	No

Expired US Patents for BACTROBAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline	BACTROBAN	mupirocin calcium	CREAM;TOPICAL	050746-001	Dec 11, 1997
Glaxosmithkline	BACTROBAN	mupirocin calcium	CREAM;TOPICAL	050746-001	Dec 11, 1997
Glaxosmithkline	BACTROBAN	mupirocin calcium	OINTMENT;NASAL	050703-001	Sep 18, 1995

International Patents for BACTROBAN

See the table below for patents covering BACTROBAN around the world.

Country	Patent Number	Title	Estimated Expiration
Romania	112987
Denmark	164506
Spain	544329
Norway	171593
New Zealand	275282	PHARMACEUTICAL COMPOSITION WITH A CREAM BASE CONTAINING A MINERAL OIL, FATTY ALCOHOL(S) AND/OR FATTY ESTER(S), A POLYOXYETHYLENE ETHER OR ESTER SURFACTANT AND WATER
Spain	8604249
Mexico	163401	UN PROCEDIMIENTO PARA PREPARAR PSEUDOMONATO CALCICO CRISTALINO O UN HIDRATO DEL MISMO

BACTROBAN Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for BACTROBAN

Introduction to BACTROBAN

BACTROBAN, also known by its active ingredient mupirocin, is a topical antibiotic used to treat various skin infections. It is widely recognized for its efficacy in combating bacterial infections such as impetigo and methicillin-resistant Staphylococcus aureus (MRSA).

Market Size and Growth

The global mupirocin market, which includes BACTROBAN, has been experiencing significant growth. As of 2023, the global mupirocin market size was substantial, and it is projected to continue growing at a notable compound annual growth rate (CAGR) from 2024 to 2031[1].

Segment Analysis

The mupirocin market is segmented into various types and applications:

• Types: The market includes cream, ointment, and other formulations. The cream segment accounted for a noticeable share of the global mupirocin market in 2023 and is expected to experience significant growth in the near future[1].
• Applications: Primary infections are a major application segment, expected to expand at a significant CAGR throughout the forecast period[1].

Regional Analysis

The market is geographically segmented into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. Each region provides insights into revenue share, current trends, and growth prospects. For instance, the Asia Pacific region is expected to show broad-based growth across various categories, although it may face challenges in the pain relief segment due to comparative data from previous years[2][5].

Key Players and Strategies

Major companies like GlaxoSmithKline (GSK) and Cardinal Health are key players in the mupirocin market. These companies are focusing on strategy building to strengthen their product portfolios and expand their business globally. For example, GSK, now part of Haleon after the spin-off, continues to invest in research and development and brand marketing to drive growth[2][5].

Market Drivers and Opportunities

Several factors drive the growth of the mupirocin market:

• Increasing Incidence of Skin Infections: The rising incidence of skin infections, including MRSA and other bacterial infections, is a significant driver.
• Advancements in Topical Drug Delivery: Innovations in topical drug delivery systems enhance the efficacy and convenience of mupirocin, contributing to market growth[3].
• Growing Demand for Self-Administration: The increasing demand for self-administration and home care products also boosts the market[3].

Market Restraints and Challenges

Despite the growth, the market faces several challenges:

• Competition from Generic Products: The availability of generic versions of mupirocin can reduce the market share of branded products like BACTROBAN.
• Regulatory Hurdles: Strict regulatory requirements and the need for continuous innovation to stay ahead in the market can be challenging[1].

Financial Performance

The financial performance of companies involved in the mupirocin market is robust, with significant revenue growth:

• Revenue Growth: Haleon, for instance, reported solid organic revenue growth in the first half of 2024, with a 3.5% increase, driven by strong performance in Oral Health and VMS segments, although the overall reported revenue was slightly impacted by foreign exchange and M&A activities[2][5].
• Operating Profit: The company also saw an 11% increase in organic operating profit, driven by operating leverage, lower cost inflation, and productivity savings[5].

Future Outlook

The medium-term outlook for the mupirocin market is positive:

• Growth Projections: The market is expected to continue growing, driven by increasing demand for topical antibiotic treatments and advancements in drug delivery systems.
• Strategic Initiatives: Companies are expected to continue investing in research and development, digitalization, and process automation to enhance their market position[1][5].

Consumer Behavior and Market Trends

Consumer behavior plays a crucial role in shaping the market:

• Preference for Convenience: Consumers increasingly prefer self-administration and home care products, which is driving the demand for topical antibiotics like mupirocin[3].
• Awareness of Skin Health: Growing awareness about skin health and the importance of treating skin infections effectively is another trend influencing the market[1].

Technological and Regulatory Trends

Technological advancements and regulatory changes are also significant:

• Innovations in Drug Delivery: Advances in transdermal drug delivery systems are enhancing the efficacy and user experience of mupirocin products.
• Regulatory Compliance: Companies must comply with stringent regulatory requirements, which can impact the development and launch of new products[3].

Key Takeaways

• The global mupirocin market is growing significantly, driven by increasing skin infection incidence and advancements in drug delivery.
• Key players are focusing on strategy building and innovation to expand their market share.
• The market faces challenges from generic competition and regulatory hurdles.
• Financial performance is robust, with solid organic revenue and operating profit growth.
• Future outlook is positive, with continued growth expected due to increasing demand and strategic initiatives.

Frequently Asked Questions (FAQs)

1. What is the current market size of the global mupirocin market? The global mupirocin market size was substantial in 2023, with detailed figures available in market reports[1].

2. What is the projected growth rate of the mupirocin market? The mupirocin market is projected to grow at a notable CAGR from 2024 to 2031[1].

3. Which segment of the mupirocin market is expected to grow the most? The cream segment and primary infection application segment are expected to experience significant growth in the near future[1].

4. Who are the key players in the mupirocin market? Major companies like GlaxoSmithKline (GSK) and Cardinal Health are key players in the mupirocin market[2][5].

5. What are the main drivers of the mupirocin market growth? The main drivers include the increasing incidence of skin infections, advancements in topical drug delivery systems, and growing demand for self-administration and home care products[1][3].

Cited Sources:

1. Cognitivemarketresearch.com - Mupirocin Market Report 2024 (Global Edition)
2. Haleon.com - 2024 Half year results - Haleon
3. MarketsandMarkets.com - Topical Drug Delivery Market Growth, Drivers, and Opportunities
4. Marketresearchintellect.com - Global Bactroban Ointment Market Size, Scope And Forecast Report
5. Haleon.com - 2024 Half year results - Haleon Press Release